Hilde Carlier

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena et al. · Arthritis & Rheumatology · 2018 · 233 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 214 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2019 · 126 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto et al. · The Journal of Rheumatology · 2017 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16